Ru(II)–arene complexes with N-substituted 3,4-dihydroquinazoline ligands and catalytic activity for transfer hydrogenation reaction
摘要:
In this study, N-coordinated 3,4-dihydroquinazoline ruthenium(II) complexes were synthesized by the cleavage reaction of [RuCl2(p-cymene)](2) wit h N-substituted 3,4-dihydroquinazolines. In addition, the X-ray crystal structure of 2,4,6-trimethylbenzyl substituted 3,4-dihydroquinazoline Ru(II) complex (1a) is reported. Furthermore, the resulting piano-stool complexes were evaluated as transfer hydrogenation catalysts for reduction of acetophenone in the presence of 2-propanol and KOH at 82 degrees C. All the complexes showed good to excellent performance after 1 h in the conversion of acetophenone to alcohol and the reaction rate was found to be sensitive to changes on the N-substituent. Additionally, the most active catalyst 1a was used in trans fer hydrogenation of different ketones to investigate the effect of substituents on ketones. (C) 2013 Elsevier B.V. All rights reserved.
Ru(II)–arene complexes with N-substituted 3,4-dihydroquinazoline ligands and catalytic activity for transfer hydrogenation reaction
摘要:
In this study, N-coordinated 3,4-dihydroquinazoline ruthenium(II) complexes were synthesized by the cleavage reaction of [RuCl2(p-cymene)](2) wit h N-substituted 3,4-dihydroquinazolines. In addition, the X-ray crystal structure of 2,4,6-trimethylbenzyl substituted 3,4-dihydroquinazoline Ru(II) complex (1a) is reported. Furthermore, the resulting piano-stool complexes were evaluated as transfer hydrogenation catalysts for reduction of acetophenone in the presence of 2-propanol and KOH at 82 degrees C. All the complexes showed good to excellent performance after 1 h in the conversion of acetophenone to alcohol and the reaction rate was found to be sensitive to changes on the N-substituent. Additionally, the most active catalyst 1a was used in trans fer hydrogenation of different ketones to investigate the effect of substituents on ketones. (C) 2013 Elsevier B.V. All rights reserved.
HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS
申请人:Amberg Wilhelm
公开号:US20100041698A1
公开(公告)日:2010-02-18
The invention relates to compounds of general formula (I), corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof and the prodrugs of said compounds. The invention also relates to the use of said compounds as binding partners for 5-HT5 receptors for treating diseases that are modulated by a 5-HT5 receptor activity, in particular, for treating neurodegenerative and neuropsychiatric disorders as well as signs, symptoms and dysfunctions.